Member Info for Bobbler

Colbatblue, everything you say is true. Thanks for sharing. I just hope those silly HNWI are reading this,!it’s such a shame they didn’t have someone like you to guide them, the world is so unfair.

Once again thanks for sharing your knowledge with the BB. I’m guessing you’re not invested here (why would you be) which makes the sharing of your knowledge so much more generous. Thumbs up from me.

As its a bit of a slow news day I thought i would have a look at who the likely organisation is that Saruem are working "alongside with". Ref latest RNS.
"Sareum, working alongside a specialist contract research organisation (CRO). The CRO conducting and managing the studies has extensive experience in conducting trials in inflammatory diseases and will recruit up to 120 subjects at a site in Manchester, UK."

My reckoning is that they are working with Manchester Clinical Trials Unit.
https://www.bmh.manchester.ac.uk/research/manchester-ctu/
Which states "We are home to a number of centres of excellence, including those funded by charities and industry. "
https://www.mccir.manchester.ac.uk/research/

Of particular relevance would be: https://www.mccir.manchester.ac.uk/research/areas/skin-inflammation/

This would certainly fit and the use of the word "organisation" would indicate its a larger group they are working alongside.

Please note: positive RNS is a beacon for C wombles

Morning Stoney, ref your last sentence.
I think that’s exactly what Tim is suggesting:

“Sareum believes that TYK2/JAK1 inhibition offers potential for increased efficacy in psoriasis, compared with existing approved therapies.”

All good.

With regards to the bloomberg article "GSK Poaches Top AstraZeneca Dealmakers to Boost Drug Pipeline"

"Garrett Rhyasen has also started at GSK this month as vice president of oncology search and evaluation. Rhyasen had been at AstraZeneca about three years, most recently leading the business development team’s global search and evaluation efforts in oncology, according to LinkedIn. "

Garrett published an article back in 2015 which listed Sareum in the Chk1 competitive landscape. If nothing else he should certainly be aware of Sareum.

http://oncologydiscovery.com/2015/08/08/strategies-to-enhance-patient-responses-to-checkpoint-inhibitors/

https://www.bloomberg.com/news/articles/2022-06-29/gsk-poaches-astrazeneca-s-sheldon-for-business-development-role

Ashpot, as others have said, stay positive. Sounds like it’s been a quick response from diagnosis to treatment, which as I’m sure you’re away is extremely important and a very positive action. All the very best to you and your wife.

HBD - cap suitable doffed sir.

Warthog. The biggest purchase most people make is when they buy a home (if they are indeed lucky enough to be able to get on the property ladder). No one is really privileged as to what the property market will do, it might crash it might boom?

Comparing it to getting on a commercial aircraft and hoping the pilot has received the correct training is hardly a grown up comparison.

Best to shed all clothing in this weather. Au naturelle

Happy for him to tweet about his choice of underpants as long as it keeps the SP on an upward trajectory.

Are we off to Button Moon ?

https://m.youtube.com/watch?v=f20BLJGHNXY

Blocky.
I think technically the bottom is where the hole is located.

Kat, I certainly have to agree with your final sentence.

Honesty is always the best policy. Thumbs up to you.

Never a good sign when the Doctors wearing a glove commonly seen on the arm of a farming veterinarian

Pfizer, Roivant Unveil Priovant with High Potential TYK2/JAK1 Inhibitor

https://www.fiercebiotech.com/biotech/mystery-solved-roivant-pfizers-tyk2-partner-and-cutting-other-programs-fund-late-phase

Morning SOG. Below link details US patent application made by Sierra in relation to SRA737 and Parpi

https://patents.justia.com/patent/20210077499

ref the named inventors as follows:
Inventor John Charles Reader, Jamie Conor MARSHALL, John Mykytiuk, Julian Scott Northen

Jamie Conor Marhsall: Senior Solid State Scientist at Sterling Pharma Solutions
John Mykytiuk : Solid State Manager Sterling Pharma Solutions - Uiversity of Bradford
Julian Scott Northern - Onyx Scientific (current position may well have been previously been with Sterling)

Reminds me of a Specials track………escape they have

Celtic, the authors are what you might called pretty credible:-)

Published March 2020 but still a very encouraging read.

“Combined treatment with SRA737 and an experimental inhibitor of B-family DNA polymerases called aphidicolin stripped cancer cells of their ability to cope with DNA damage, and was more effective at killing them in eight of the nine cancer cell lines tested.”

https://www.icr.ac.uk/news-archive/two-pronged-attack-on-dna-repair-could-kill-drug-resistant-cancers